CD19 and non-Hodgkin lymphoma: A phase I/IIa clinical trial (NCT03056339) of IL-15-expressing cord blood-derived CD19-CAR-NK cells for the treatment of relapsed or refractory CD19-positive non-Hodgkin's lymphoma or chronic lymphocytic leukemia was conducted and completed at the University of Texas MD Anderson Cancer Center [40,112].